psbA mutation (Ala251 to Val) in Chenopodium album resistant to triazinones

C

Chlorophyll fluorescence tests for monitoring triazinone resistance in Chenopodium album L.

Recently, fat-hen (Chenopodium album L.) biotypes resistant to metamitron, a key herbicide in sugar beet, were recorded. Pot experiments revealed that these biotypes showed cross-resistance to metribuzin, a triazinone used in potato. Greenhouse and laboratory experiments were performed to develop resistance monitoring tests, so that resistant biotypes can be detected quickly and farmers may adapt their weed management. Resistant and susceptible biotypes were grown in a greenhouse under conditions of natural and artificial light at an intensity of 100 μmol photons m-2 s-1. Leaves were collected and, immersed in a solution of 1000 μM metamitron and 500 μM metribuzin, exposed to natural and artificial light (1000, 750 and 100 μmol photons m-2 s-1 respectively). After this, chlorophyll fluorescence measurements were carried out. The results revealed that the photosynthetic electron transport of metamitron- and metribuzin-incubated leaves of resistant biotypes decreased less than that of the incubated leaves of susceptible biotypes. The differences between the metribuzin-incubated leaves of the susceptible and resistant biotypes were larger than those observed with the metamitron-incubated leaves. The aim of the experiments was to optimise the chlorophyll fluorescence test and to find a sufficiently high correlation between the results of the pot experiments and the chlorophyll fluorescence measurements

Effect of Root Storage and Forcing on the Carbohydrate and Secondary Metabolite Compostion of Belgian Endive (Cichorium intybus L. Var. foliosum)

Belgian endive is grown in a two-step cultivation process that involves growing of the plants in the field, cold storage of the taproots, and a second growth period in dark conditions called forcing to yield the witloof heads. In this study, the changes in the carbohydrate content and the secondary metabolite composition were studied in different tissues of Belgian endive during the cultivation process. Belgian endive heads contain between 336–388 mg/g DW of total soluble carbohydrates, predominantly fructose and glucose. The heads also contain phenolic compounds and terpenoids that give Belgian endive its characteristic bitter taste. The terpenoid and phenolic compound composition of the heads was found to be constant during the cultivation season, regardless of the root storage time. In roots, the main storage carbohydrate, inulin, was degraded during storage and forcing processes; however, more than 70% of total soluble carbohydrates remained unused after forcing. Additionally, high amounts of phenolics and terpenoids were found in the Belgian endive taproots, predominantly chlorogenic acid, isochlorogenic acid A, and sesquiterpene lactones. As shown in this study, Belgian endive taproots, which are currently discarded after forcing, are rich in carbohydrates, terpenes, and phenolic compounds and therefore have the potential for further valorization. This systematic study contributes to the understanding of the carbohydrate and secondary metabolite metabolism during the cultivation process of Belgian endiv

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA